SCHEMBL4358518

SCHEMBL4358518

CC(C)(C)CC(C)(C)NC(=S)Nc1cc(Cl)cc(Cl)c1O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 4/20 0.46
POLB P06746 3/20 0.46
LMNA P02545 5/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
GAA P10253 2/20 0.40
HSPA5 P11021 1/20 0.40
ALDH1A1 P00352 7/20 0.38
MEN1 O00255 6/20 0.37
KMT2A Q03164 6/20 0.37
MAPT P10636 5/20 0.37
KDM4E B2RXH2 2/20 0.36
AGTR1 P30556 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
CYP3A4 P08684 1/20 0.35
TSHR P16473 1/20 0.35
RECQL P46063 1/20 0.35
HSD17B10 Q99714 1/20 0.35
ALOX12 P18054 2/20 0.35
TP53 P04637 1/20 0.35
XBP1 P17861 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4344513 0.84 POLB (0.55) HTTPOLBLMNASMN1; SMN2GAA
SCHEMBL4341826 0.83 HSPA5 (0.46) HTTPOLBSMN1; SMN2HSPA5ALDH1A1
SCHEMBL4350137 0.83 POLB (0.41) HTTPOLBLMNASMN1; SMN2GAA
SCHEMBL4345688 0.81 HTT (0.56) HTTPOLBLMNASMN1; SMN2GAA
SCHEMBL4357518 0.81 POLB (0.47) HTTPOLBLMNASMN1; SMN2GAA
SCHEMBL4345664 0.81 POLB (0.49) HTTPOLBLMNASMN1; SMN2GAA
SCHEMBL4352955 0.81 HTT (0.52) HTTPOLBLMNAALDH1A1MEN1
SCHEMBL4350392 0.73 HTT (0.44) HTTPOLBLMNASMN1; SMN2GAA
SCHEMBL4343912 0.73 HTT (0.47) HTTPOLBLMNASMN1; SMN2GAA
SCHEMBL4350868 0.72 SMN1; SMN2 (0.55) HTTPOLBLMNASMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 HTT 3824/4885POLB 3571/4885LMNA 3160/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 HTT 3995/4885POLB 2402/4885LMNA 3661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.